Market closed

Beam Therapeutics/$BEAM

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Ticker

$BEAM
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

472
Website
beamtx.com

BEAM Metrics

BasicAdvanced
$2B
-
-$1.75
1.86
-

$2B

1.86

$49.50

$20.84

1.1M

5.688

5.569

18.846

20.48

-9.27%

-18.29%

5.977

2.56

2.56

-14.377

328.73%

-58.25%

664.99%

-35.50%

What the Analysts think about BEAM

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.

BEAM Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BEAM Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

BEAM News

AllArticlesVideos
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

GlobeNewsWire·2 days ago
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy

2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy

Schaeffers Research·5 days ago
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BEAM

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Beam Therapeutics stock?

Beam Therapeutics (BEAM) has a market cap of $2B as of January 15, 2025.

What is the P/E ratio for Beam Therapeutics stock?

The price to earnings (P/E) ratio for Beam Therapeutics (BEAM) stock is 0 as of January 15, 2025.

Does Beam Therapeutics stock pay dividends?

No, Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Beam Therapeutics dividend payment date?

Beam Therapeutics (BEAM) stock does not pay dividends to its shareholders.

What is the beta indicator for Beam Therapeutics?

Beam Therapeutics (BEAM) has a beta rating of 1.86. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.